ACCESS TO MEDICINES:
Advancing Innovative Healthcare

Takeda's Access to Medicines **(AtM)** approach is an integral part of our commitment to improving lives worldwide. Our ambition is to increase access to innovative medicines and vaccines and elevate standards of healthcare for complex and rare diseases.

Through our Access to Medicines initiatives, we focus our efforts on lower- and middle-income countries with less developed healthcare systems primarily across Southeast Asia, Latin America, and Sub-Saharan Africa.

There are 2 billion people around the world without proper access to medicines

We want to support communities who are unable to access innovative medicines and quality treatment when faced with serious, complex, and rare diseases.

Our approach focuses on

Six therapeutic areas spanning oncology, rare diseases, vaccines, plasma-derived therapies, gastroenterology, and neuroscience

- Oncology
- Rare Disease
- Neuroscience
- Gastro-enterology
- Plasma-derived therapies
- Vaccines

Interventions to support patients including disease awareness, patient care and support

End-to-end access, from drug development to long-term patient care

Our programmes have unlocked better care for millions of patients

Takeda Patient Assistance Programs have been implemented in **15** countries and territories benefitting more than **5,500** patients with rare and complex diseases, reaching **35 - 40%**** more patients than would otherwise have access to medicines

Blueprint for Innovative Healthcare Access in Kenya screened more than **46,000** people for cancer, diabetes, and hypertension and provided patients with treatment and support

Under Takeda's **shared value programs, 26,000** undergraduate students have been trained, enabled **1,800** graduate students to complete PhDs/further studies and equipped **2,000** researchers to conduct research on diseases

Knowledge sharing collaborations over **200** R&D employees have trained 20 NGO partners across **50** different healthcare initiatives

Empowered recipients of the **Instrumental Access Program** to gain **$3.4 million** in new research awards

Structured donations including **1,000** pieces of scientific instrumentation donated to **67** research departments across **23** countries

* Cumulative number of patients from program inception until end December 2020.
** Takeda PAP for Adcetris in Egypt between 2016 and 2020

We are committed to achieving better health for a brighter future

Collaborating with policy makers and advocacy groups to strengthen ecosystems and accelerate patient access

Addressing access barriers in local health systems to provide high-quality patient care

Building innovative programs that improve patient access to medicines and treatments

Our Access to Medicines initiatives are recognised by experts in the industry

Ranked **6th** on the 2021 Access to Medicine Index

Emerged **1st** in 'Governance of Access' on the 2021 AtM Index

Amongst **top 10** for all three technical areas evaluated on the 2021 AtM Index

Top climber in the Dow Jones Sustainability Indices in 2019

> We want our innovations to have a purpose and improve the lives of people who need them, no matter where they live or their ability to pay.

Christophe Weber,
President & CEO,
Takeda

View the full Access to Medicines Progress Report here

EM-0821 Date of Preparation; October, 2021